Abstract
Objective
Solifenacin succinate (YM905; Vesicare®) is a promising new bladder selective muscarinic receptor antagonist under investigation for the treatment of overactive bladder. This study was designed to assess the absolute bioavailability of a single oral dose of solifenacin 10mg, which is twice the suggested starting dose.
Study design
Single-centre, open-label, randomised, two-period, crossover, single-dose study.
Methods
Solifenacin was administered orally as a 10mg dose and intravenously as a 5mg dose. Oral and intravenous (IV) doses were divided by a washout period of ≥14 days.
Study participants
The study group consisted of 12 healthy young men, aged 20–45 years, nine of whom completed the study.
Results
The pharmacokinetic analysis comprised nine subjects. A single oral dose of solifenacin 10mg had a high absolute bioavailability of 88.0% (95% confidence interval 75.8, 102.1), low clearance (9.39 L/h [SD 2.68]), and an extensive mean volume of distribution at steady state (599L [SD 86]). Only 7% of solifenacin was excreted intact in the urine. Single oral and IV administration of solifenacin was well tolerated in this study. The most common adverse events related to drug treatment were headache and somnolence.
Conclusions
Pharmacokinetic analyses of single oral and IV doses of solifenacin demonstrated that the drug has a high absolute oral availability of 88%. This finding suggests that solifenacin may have a higher and less variable bioavailability than other antimuscarinic agents.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Abrams P, Cardozo L, Fall M, et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167–78
Wyndaele JJ. The overactive bladder. BJU Int 2001; 88: 135–40
Stewart W, Herzog R, Wein A, et al. The prevalence and impact of overactive bladder in the US: results from the NOBLE program. Neurourol Urodyn 2001; 20: 406–8
Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care 2000; 6: S565–73
Abrams P, Kelleher CJ, Kerr L, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000; 6 Suppl. 11: S580–90
Cardozo L, Kuzmin I, Lisec ML, et al. YM905 in symptomatic overactive bladder: results of a Phase 3A randomised, placebo-controlled trial [abstract]. J Urol 2003; 169 Suppl. 4: 350
Chapple CR, Araño P, Bosch JLHR, et al. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a European placebo- and tolterodine-controlled, phase II, dose-finding study [abstract]. Neurourol Urodyn 2002; 21: 381–2
Smith N, Grimes I, Ridge S, et al. YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002
Ikeda K, Kobayashi S, Suzuki M, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 97–103
Smulders RA, Krauwinkel W, Abila B, et al. 10- and 20-mg oral doses of YM905, a novel, bladder-selective antimuscarinic: pharmacokinetics, pharmacodynamics, and safety in healthy, elderly men and women [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002
Smith N, van Zijtfeld J, Swart PJ. Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM905 [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002
Smulders RA, Tan HT, Krauwinkel W, et al. A placebo-controlled, dose-rising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of YM905 [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002
Smulders RA, van Alphen WW, Visser JN, et al. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety, tolerability, and pharmacokinetics [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002
Uchida T, Smulders RA, Abila B, et al. Pharmacokinetics of YM905, a novel, bladder-selective antimuscarinic, are not adversely affected by food [abstract]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 28–30: Heidelberg. Heidelberg: ICS 2002
Douchamps J, Derenne F, Stockis A, et al. The pharmaco-kinetics of oxybutynin in man. Eur J Clin Pharmacol 1988; 35: 515–20
Brynne N, Stahl MMS, Hallen B, et al. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997; 35: 287–95
Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001; 40: 227–35
Acknowledgements
This study was supported by Yamanouchi Pharmaceutical Co. Ltd., Tokyo, Japan. The authors have no conflicts of interest directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kuipers, M.E., Krauwinkel, W.J.J., Mulder, H. et al. Solifenacin Demonstrates High Absolute Bioavailability in Healthy Men. Drugs R D 5, 73–81 (2004). https://doi.org/10.2165/00126839-200405020-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200405020-00002